Novartis to expand renal portfolio with Chinook Therapeutics acquisition

Pallavi Madhiraju- June 12, 2023 0

Novartis has announced its agreement to acquire Chinook Therapeutics, a clinical stage biopharmaceutical company based in Seattle, Washington in a deal worth up to around ... Read More

AstraZeneca wraps up $1.8bn acquisition of CinCor Pharma

Raghuram Kadari- February 28, 2023 0

AstraZeneca has closed the previously announced $1.8 billion acquisition of US biopharmaceutical company CinCor Pharma. Under the terms of the agreement, AstraZeneca acquired all outstanding ... Read More

GSK gets Jesduvroq FDA approval for anaemia of chronic kidney disease

Raghuram Kadari- February 4, 2023 0

GSK has secured the approval of the US Food and Drug Administration (FDA) for the company’s Jesduvroq (daprodustat) for anaemia of chronic kidney disease (CKD) ... Read More

AstraZeneca to acquire US biopharma company CinCor Pharma for $1.8bn

Raghuram Kadari- January 10, 2023 0

AstraZeneca has agreed to acquire CinCor Pharma for a transaction value of around $1.8 billion, which includes an upfront cash payment of about $1.3 billion, ... Read More

AstraZeneca Pharma India gets Dapagliflozin 10mg import and market permission from CDSCO

Pallavi Madhiraju- November 27, 2022 0

AstraZeneca Pharma India has secured an import and market permission for Dapagliflozin (Forxiga) tablets of 10 mg from India’s Central Drugs Standard Control Organisation (CDSCO), ... Read More

Cara Therapeutics, VFMCRP get EC approval for Kapruvia for pruritus

pallavi123- May 1, 2022 0

Cara Therapeutics and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) said that Kapruvia (difelikefalin) has secured approval from the European Commission (EC) for the treatment ... Read More

Japan approves Roxadustat for non-dialysis anemia in chronic kidney disease

pharmanewsdaily- November 28, 2020 0

Astellas Pharma and FibroGen have received approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the extended use of EVRENZO (roxadustat) in adults ... Read More

AstraZeneca’s Farxiga receives FDA breakthrough therapy designation for chronic kidney disease treatment

pharmanewsdaily- October 4, 2020 0

AstraZeneca's Farxiga (dapagliflozin), a leading drug in the management of chronic kidney disease (CKD), has been granted Breakthrough Therapy Designation (BTD) by the US Food ... Read More